logo
New Report: 72 Million Adults in the US Lack Dental Insurance, Nearly Three Times the Number Without Health Insurance

New Report: 72 Million Adults in the US Lack Dental Insurance, Nearly Three Times the Number Without Health Insurance

Business Wire21-05-2025

BOSTON--(BUSINESS WIRE)-- A new report from CareQuest Institute for Oral Health ® reveals that 27% of US adults — an estimated 72 million people — do not have dental insurance, nearly three times the number of adults who lack health insurance (9.5%, or 26 million). The findings, from the latest State of Oral Health Equity in America (SOHEA) survey, underscore a persistent and troubling gap in access to dental care.
Lack of dental insurance puts adults at risk for delayed treatment and worsening oral health, which is closely tied to broader health problems, including diabetes, heart disease, and even dementia.
'These findings reinforce the fact that oral health care is too expensive and out of reach for too many families in America,' said Melissa Burroughs, Senior Director of Public Policy at CareQuest Institute. 'Gaps in dental insurance force families to make impossible tradeoffs between things like putting food on the table and getting the care they need — any cuts to the Medicaid program would only make this problem worse. It's time for policy solutions that address our nation's oral health, starting by preserving Medicaid adult dental coverage.'
The report, Out of Pocket: A Snapshot of Adults' Dental and Medical Care Coverage, also finds that:
Adults with lower incomes and education levels are more likely to lack dental insurance. 40% of adults without a high school diploma and 38% of those earning under $30,000 annually are uninsured for dental care.
One-third of adults with Medicare or Medicaid lack dental coverage. Traditional Medicare does not include dental services, and Medicaid adult dental coverage varies widely by state.
More than 80% of adults without health insurance also lack dental insurance.
Nearly one in four adults with dental insurance gained it in the last year, either by changing from a previous insurance plan to a new plan or by enrolling in an insurance plan after being uninsured.
Among adults currently without dental insurance, 12% lost coverage in the past year, disproportionately affecting younger adults and Asian/Pacific Islander, Black, and Hispanic adults.
Despite growing recognition that oral health is essential to overall health, significant policy gaps remain. Medicare does not guarantee dental coverage, Medicaid coverage for adults is optional and inconsistent across states, and marketplace dental plans often lack affordability and accessibility, with no subsidies available.
The SOHEA survey is the largest nationally representative survey focused exclusively on oral health attitudes, behaviors, and experiences among adults. Conducted from March to May 2024 by the National Opinion Research Center (NORC) at the University of Chicago, the study reflects the voices of more than 9,000 adults nationwide.
The full report is available here.
About CareQuest Institute for Oral Health ®
CareQuest Institute for Oral Health ® is a national nonprofit championing a more equitable future where every person can reach their full potential through excellent health. We do this through our work in philanthropy, analytics and data insights, health transformation, policy and advocacy, and education, as well as our leadership in dental benefits and innovation advancements. We collaborate with thought leaders, health care providers, patients, and local, state, and federal stakeholders to accelerate oral health care transformation and create a system designed for everyone. To learn more, visit carequest.org and follow us on Twitter/X, LinkedIn, Facebook, and Instagram.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novel T Cell Measurement System by Novoviah Pharmaceuticals Demonstrates High Accuracy for Clinical Disease Detection and Monitoring of Celiac Disease
Novel T Cell Measurement System by Novoviah Pharmaceuticals Demonstrates High Accuracy for Clinical Disease Detection and Monitoring of Celiac Disease

Yahoo

time37 minutes ago

  • Yahoo

Novel T Cell Measurement System by Novoviah Pharmaceuticals Demonstrates High Accuracy for Clinical Disease Detection and Monitoring of Celiac Disease

BRISBANE, Australia, June 10, 2025--(BUSINESS WIRE)--Novoviah Pharmaceuticals announces that their novel clinical platform technology for detecting and monitoring disease by measuring immune reactivity has been successfully tested in Celiac Disease, with results published in Gastroenterology. The NovoleukinTM test platform, developed specifically for clinical use, measures T Cell reactivity in fresh whole blood after 24-hour in vitro stimulation with a target antigen. The proprietary technology boosts T Cell activity after blood collection, enabling accurate cytokine biomarker measurement and comparison with unstimulated controls. This can be used to monitor disease reactivity status and the effectiveness of prospective therapeutics. Originally developed for multi-center clinical trials, the NovoleukinTM system has potential for broader clinical use. Its utility and performance were demonstrated in collaboration with WEHI researchers who analyzed blood samples from 181 volunteers to identify the presence and assess the severity of celiac disease. The results show high sensitivity (90%) and specificity (95%) in detecting celiac disease, even in patients following a strict gluten free diet which normally confounds traditional diagnostic methods. The test detects as few as one gluten-specific T lymphocyte in one milliliter of blood or one per million CD4+ T cells. This level of sensitivity in a straightforward blood test is a landmark technical achievement and promises to impact patient care in many fields and accelerate immunotherapy and vaccine development. Associate Professor Jason Tye-Din, Head of WEHI's Celiac Research Laboratory and a gastroenterologist at the Royal Melbourne Hospital, highlighted the test's promise for simplifying diagnosis and removing a significant barrier in current diagnostics. "By stimulating T cells after a blood draw, patients can avoid the need to return to gluten and the suffering that often comes with that – for the sole purpose of diagnosis. That is a major step towards improving outcomes for patients." The test was also predictive of patient responses during gluten challenge protocols, underscoring its utility in stratifying patients for clinical research and tailoring therapeutic strategies. Dr Robert Anderson, co-founder of Novoviah Pharmaceuticals, current President of the International Society for the Study of Celiac Disease and a practicing gastroenterologist, said the study highlights the potential of practical, blood-based T cell diagnostics in clinic and for clinical trials. "The test is designed for ease of use in the clinical setting. It can be prepared without specialist equipment and then sent for highly sensitive laboratory analysis. The protocol is simple and reproducible enabling easy rollout across multiple sites," Dr Anderson said. The Novoleukin test's ability to detect disease and measure changes in immune response has proven invaluable in the developmental journey for drug developers. "Non-invasively monitoring T cell reactivity opens the door to transformative clinical applications, particularly in drug development," Dr Anderson added. "The platform is already being used by leading biopharma partners to evaluate immune responses during celiac disease clinical trials, offering real-time insights into treatment efficacy." Novoviah is actively expanding the diagnostic applications of the Novoleukin platform across additional immune-mediated diseases, including viral infection, autoimmune conditions and some cancers, aiming to bring T cell-guided insights to clinical and research settings. About Novoviah Pharmaceuticals Novoviah is a Brisbane-based biotechnology company established in 2020 to develop and supply a new best in-class NovoleukinTM antigen-specific T cell testing platform for clinical trials and explore its broader application in clinical care. Novoviah is committed to advancing sensitive and reliable clinical tests for antigen-specific T cells to support drug developers, researchers, clinicians and patients needing better treatments and diagnosis. Find out more at About WEHI (Walter and Eliza Hall Institute of Medical Research) WEHI is where brilliant minds collaborate and innovate to make life-changing scientific discoveries that help people live healthier for longer. Our medical researchers have been serving the community for more than 100 years, making transformative discoveries in cancer, infection and immunity, and lifelong health. WEHI brings together diverse and creative people with different experience and expertise to solve some of the world's most complex health problems. With partners across science, health, government, industry, and philanthropy, we are committed to long-term discovery, collaboration, and translation. At WEHI, we are brighter together. Find out more at View source version on Contacts Novoviah Pharmaceuticalskylieell@ +61413496222 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Wisp Names Jennifer Peña as Chief Medical Officer to Support Integrated Women's Telehealth
Wisp Names Jennifer Peña as Chief Medical Officer to Support Integrated Women's Telehealth

Business Wire

time43 minutes ago

  • Business Wire

Wisp Names Jennifer Peña as Chief Medical Officer to Support Integrated Women's Telehealth

NEW YORK--(BUSINESS WIRE)-- Wisp, the largest pure play women's telehealth company in the U.S. focused on providing sexual and reproductive health solutions to more than 1.5 million customers, today announced the appointment of Jennifer Peña, MD, as the company's Chief Medical Officer. Dr. Peña will have a crucial role in driving Wisp's commitment to being the one-stop-shop for all women's health needs, as the company continues to scale new and existing offerings. As CMO, Dr. Peña will spearhead Wisp's clinical strategy, quality, and safety programs, aligning telehealth operations with the company's broader business goals. She will oversee clinical care delivery, ensuring regulatory compliance and high standards of patient care, while guiding product development and expanding protocols for new verticals. Dr. Peña will mentor and grow a multidisciplinary clinical team, establish KPIs to benchmark performance, and collaborate cross-functionally to integrate clinical insight into Wisp's innovation and execution. As a clinical expert, she will serve as a key advisor to internal and external stakeholders as Wisp accelerates its growth. 'Wisp is committed to delivering clinical excellence and expanding access to high-quality care for women nationwide,' said Monica Cepak, CEO of Wisp. 'We have already built a trusted platform serving over 1.5 million women to meet all of their health needs. As we continue to grow and remain the leading one-stop shop for women's health, Dr. Peña's clinical expertise, across traditional clinics and telehealth, will help us push the boundaries of what's possible in virtual care. Her leadership will be crucial in building the next chapter of Wisp as we double down on our commitment to bringing innovation, accessibility, and quality care into the women's health space.' Dr. Peña brings 20 years of clinical and leadership experience across the healthcare ecosystem. As a board-certified internal medicine physician, she previously served as Medical Director for Oscar Health and Chief Medical Officer for Nurx, K Health, and Vault Health, where she led teams that delivered high-quality, tech-enabled care to diverse populations. Before that, she served as a U.S. Army physician and White House physician. Dr. Peña earned her MD from the University of Pittsburgh School of Medicine and her undergraduate degree from Yale University. 'Wisp is redefining access to sexual and reproductive health with clinical excellence and unmatched convenience,' said Dr. Jennifer Peña, Chief Medical Officer at Wisp. 'I'm thrilled to join a company that is breaking down barriers and reimagining what care looks like, whether that's delivering at-home STI testing, affordable BV treatment, effective UTI prevention or evidence-based menopause support. We're not just offering telehealth; we're building a movement to destigmatize women's health and set a new, human-centered standard for virtual care." ABOUT WISP: Wisp is the largest pure play women's telehealth company in the U.S. focused on providing sexual and reproductive health solutions to its more than 1.4 million patients in all 50 states. Offering discreet treatments online with a comprehensive selection of first-to-market products and telehealth services, Wisp has solidified itself as the one-stop shop for all women's health needs. Wisp is committed to making women's healthcare more inclusive, cost-effective, and accessible for all, addressing all stages of her healthcare journey, from her birth control, to fertility, menopause, STI diagnostics, weight care and more. Wisp has been named Fast Company's Most Innovative Companies of 2023 and Inc.'s Best in Business in 2024. Wisp is a growing and profitable company and is majority-owned by WELL Health Technologies Corp. To learn more, please visit or follow @hellowisp on Facebook, Instagram, TikTok and YouTube.

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025
Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025

Business Wire

timean hour ago

  • Business Wire

Median Technologies: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital as of May 31, 2025

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (Paris:ALMDT): About Median Technologies: Pioneering innovative software as a medical device and imaging services, Median Technologies harnesses cutting-edge AI to enhance the accuracy of early cancer diagnoses and treatments. Median's offerings include iCRO, which provides medical image analysis and management in oncology trials, and eyonis®, an AI/ML tech-based suite of software as a medical device (SaMD). Median empowers biopharmaceutical entities and clinicians to advance patient care and expedite the development of novel therapies. The French-based company, with a presence in the U.S. and China, trades on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is also eligible for the French SME equity savings plan scheme (PEA-PME). For more information, visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store